Priti Singh

Priti Singh has extensive work experience in the field of biology and translational sciences. Priti is currently working as a Principal Scientist at LTZ Therapeutics since April 2023. Prior to this, they worked at Bristol Myers Squibb from July 2017 to December 2020, where they held various roles including Senior Scientist in immuno-oncology drug discovery research. In this role, they played a key role in various immuno-oncology programs, investigating mechanism of action and demonstrating proof of concepts of immune-oncology targets. Priti also designed and orchestrated tumor mouse models for characterization of novel drug molecules.

Before joining Bristol Myers Squibb, Priti worked at the University of California, San Francisco as a Staff Research Associate II / Lab Manager from June 2015 to June 2017. Priti conducted research on miRNA expression and function in Group 2 innate lymphocyte cells (ILC2) and authored a high impact publication. Prior to this, they worked as a Staff Research Associate I / Lab Manager from June 2014 to May 2015.

Priti also has experience as a Graduate Research Assistant at Oregon State University, where they conducted PhD research on the Flavin Containing Monooxygenase2 (FMO2) genotype-dependent anti-tuberculosis drug Ethionamide (ETA) toxicity and bactericidal efficacy analysis. Priti adapted an in vivo model of tuberculosis for use in studying drug efficacy and toxicity.

Priti started their career as a Research Intern at Oregon State University in July 2010 and also worked as a Graduate Research Assistant at West Bengal University of Technology from July 2007 to July 2009.

Overall, Priti Singh has a strong background in biology and translational sciences, with expertise in immuno-oncology research and drug discovery.

Priti Singh's education history consists of three significant milestones. Priti began their educational journey at West Bengal University of Technology in Kolkata, where they pursued their M. Tech. with thesis in Biotechnology from 2007 to 2009. Following that, they enrolled at Oregon State University, where they completed their M.S. with thesis in Toxicology between 2011 and 2014. Most recently, in 2021, Priti Singh attended Harvard Medical School and obtained a Certificate of Achievement in HMX Pro Immunology- Immuno-oncology.